BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 1748007)

  • 1. Leuprolide with flutamide for complete androgen ablation: therapeutic alternative for advanced prostatic cancer (stage D2).
    Chime-Udeh E
    Conn Med; 1991 Sep; 55(9):526-8. PubMed ID: 1748007
    [No Abstract]   [Full Text] [Related]  

  • 2. Re: The effects of combined androgen blockade on cognitive function during the first cycle of intermittent androgen suppression in patients with prostate cancer.
    Gardiner RA; Nicol DL; Green HJ; Yaxley J; Watson R; Mactaggart P; Headley BC; Swanson C; Pakenham KI
    J Urol; 2004 Aug; 172(2):774; author reply 774-5. PubMed ID: 15247782
    [No Abstract]   [Full Text] [Related]  

  • 3. Androgen deprivation in men with prostate cancer is associated with an increased rate of bone loss.
    Preston DM; Torréns JI; Harding P; Howard RS; Duncan WE; McLeod DG
    Prostate Cancer Prostatic Dis; 2002; 5(4):304-10. PubMed ID: 12627216
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The effects of combined androgen blockade on cognitive function during the first cycle of intermittent androgen suppression in patients with prostate cancer.
    Cherrier MM; Rose AL; Higano C
    J Urol; 2003 Nov; 170(5):1808-11. PubMed ID: 14532781
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of flutamide as a second-line agent for maximum androgen blockade of hormone refractory prostate cancer.
    Nishimura K; Arichi N; Tokugawa S; Yoshioka I; Kishikawa H; Ichikawa Y
    Int J Urol; 2007 Mar; 14(3):264-7. PubMed ID: 17430272
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combination treatment versus LHRH alone in advanced prostatic cancer.
    Ferrari P; Castagnetti G; Ferrari G; Baisi B; Dotti A
    Urol Int; 1996; 56 Suppl 1():13-7. PubMed ID: 8776812
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Quality of life of asymptomatic men with nonmetastatic prostate cancer on androgen deprivation therapy.
    Herr HW; O'Sullivan M
    J Urol; 2000 Jun; 163(6):1743-6. PubMed ID: 10799173
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Maximal androgen blockade in prostatic cancer.
    Denis L
    Scand J Urol Nephrol Suppl; 1991; 138():137-44. PubMed ID: 1838427
    [No Abstract]   [Full Text] [Related]  

  • 9. Testosterone suppression in men with prostate cancer is associated with increased arterial stiffness.
    Dockery F; Bulpitt CJ; Agarwal S; Rajkumar C
    Aging Male; 2002 Dec; 5(4):216-22. PubMed ID: 12630068
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combined androgen blockade: leuprolide and flutamide versus leuprolide and placebo.
    Crawford ED; Goodman P; Blumenstein B
    Semin Urol; 1990 Aug; 8(3):154-8. PubMed ID: 2119048
    [No Abstract]   [Full Text] [Related]  

  • 11. [Application of antiandrogens on prostatic diseases].
    Takahashi S; Hasegawa F; Isurugi K
    Nihon Rinsho; 1994 Mar; 52(3):809-14. PubMed ID: 7513031
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pseudomyxoma ovariilike posttherapeutic alteration in prostatic adenocarcinoma: a distinctive pattern in patients receiving neoadjuvant androgen ablation therapy.
    Tran TA; Jennings TA; Ross JS; Nazeer T
    Am J Surg Pathol; 1998 Mar; 22(3):347-54. PubMed ID: 9500777
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Hepatic encephalopathy induced by flutamide administered for the treatment of prostatic cancer].
    Patel H; Rhee E; Zimmern PE
    J Urol (Paris); 1996; 102(3):123-5. PubMed ID: 9091557
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Total androgen ablation: American experience.
    Crawford ED; Nabors WL
    Urol Clin North Am; 1991 Feb; 18(1):55-63. PubMed ID: 1899495
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Alternative nonsteroidal antiandrogen therapy for advanced prostate cancer that relapsed after initial maximum androgen blockade.
    Suzuki H; Okihara K; Miyake H; Fujisawa M; Miyoshi S; Matsumoto T; Fujii M; Takihana Y; Usui T; Matsuda T; Ozono S; Kumon H; Ichikawa T; Miki T;
    J Urol; 2008 Sep; 180(3):921-7. PubMed ID: 18635218
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Successful treatment of stutter priapism with an antiandrogen.
    Costabile RA
    Tech Urol; 1998 Sep; 4(3):167-8. PubMed ID: 9800902
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The change in the dihydrotestosterone level in the prostate before and after androgen deprivation therapy in connection with prostate cancer aggressiveness using the Gleason score.
    Nishiyama T; Ikarashi T; Hashimoto Y; Wako K; Takahashi K
    J Urol; 2007 Oct; 178(4 Pt 1):1282-8; discussion 1288-9. PubMed ID: 17698092
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Is combined androgen blockade with bicalutamide cost-effective compared with combined androgen blockade with flutamide?
    Ramsey S; Veenstra D; Clarke L; Gandhi S; Hirsch M; Penson D
    Urology; 2005 Oct; 66(4):835-9. PubMed ID: 16230148
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A case of spinal and bulbar muscular atrophy with high-stage and high-Gleason Score prostate cancer responded to maximal androgen blockade therapy.
    Kosaka T; Miyajima A; Kikuchi E; Takahashi S; Suzuki N; Oya M
    J Androl; 2012; 33(4):563-5. PubMed ID: 21940987
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hormone ablation therapy as neoadjuvant treatment to radical prostatectomy.
    Solomon MH; McHugh TA; Dorr RP; Lee F; Siders DB
    Clin Invest Med; 1993 Dec; 16(6):532-8. PubMed ID: 8013157
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.